Title | Which is the preferred blood product for fibrinogen replacement in the bleeding patient with acquired hypofibrinogenemia-cryoprecipitate or fibrinogen concentrate? |
Publication Type | Journal Article |
Year of Publication | 2020 |
Authors | Cushing MM, Haas T, Karkouti K, Callum J |
Journal | Transfusion |
Volume | 60 Suppl 3 |
Pagination | S17-S23 |
Date Published | 2020 06 |
ISSN | 1537-2995 |
Keywords | Afibrinogenemia, Blood Safety, Factor VIII, Fibrinogen, Hemorrhage, Humans, Logistic Models |
Abstract | The importance of the targeted treatment of acquired hypofibrinogenemia during hemorrhage with a concentrated fibrinogen product (either cryoprecipitate or fibrinogen concentrate) cannot be underestimated. Fibrinogen concentrate is a pathogen inactivated, pooled product that offers a highly purified single factor concentrate. Cryoprecipitate is a pooled product that comes with a spectrum of other coagulation factors which may further enhance (additional procoagulant effect) or even disturb (prothrombotic risk) hemostasis. The pros and cons of each product are discussed. |
DOI | 10.1111/trf.15614 |
Alternate Journal | Transfusion |
PubMed ID | 32478877 |
Related Faculty:
Melissa Cushing, M.D.